GT Biopharma (GTBP) Receivables (2013 - 2014)
GT Biopharma's (GTBP) quarterly Receivables came in at $5000.0 in Q2 2014, down 83.33% quarter-over-quarter from $30000.0 in Q1 2014.
Powered by 
Analysis
GT Biopharma (GTBP) Receivables (2013 - 2014) Analysis & Trends
GT Biopharma (GTBP) has reported Receivables for 2 consecutive years, with $5000.0 the latest figure, recorded in Q2 2014.
- On a quarterly basis, Receivables changed N/A year-over-year to $5000.0 in Q2 2014; TTM through Jun 2014 was $5000.0, a N/A change from a year earlier, with the FY2013 full-year figure at $40000.0, changed N/A from the prior year.
- Receivables was $5000.0 for Q2 2014 at GT Biopharma, down from $30000.0 in the prior quarter.
- Over five years, Receivables peaked at $40000.0 in Q4 2013 and troughed at $5000.0 in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 215.33 Mn |
| 10 | GT Biopharma | 337,746.23 | 337,746.23 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2014 | 5,000.00 |
| Mar 31, 2014 | 30,000.00 |
| Dec 31, 2013 | 40,000.00 |